Olema Pharmaceuticals Inc (OLMA) - Total Assets
Based on the latest financial reports, Olema Pharmaceuticals Inc (OLMA) holds total assets worth $533.43 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See OLMA net assets for net asset value and shareholders' equity analysis.
Olema Pharmaceuticals Inc - Total Assets Trend (2018–2025)
This chart illustrates how Olema Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Olema Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Olema Pharmaceuticals Inc's total assets of $533.43 Million consist of 96.6% current assets and 3.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.1% |
| Accounts Receivable | $4.06 Million | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Olema Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Olema Pharmaceuticals Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Olema Pharmaceuticals Inc's current assets represent 96.6% of total assets in 2025, a decrease from 99.1% in 2018.
- Cash Position: Cash and equivalents constituted 9.1% of total assets in 2025, down from 96.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Olema Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Olema Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Olema Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.95 | 10.50 | 62.59 |
| Quick Ratio | 9.95 | 10.50 | 62.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $463.65 Million | $396.71 Million | $324.99 Million |
Olema Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Olema Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.67 |
| Latest Market Cap to Assets Ratio | 2.22 |
| Asset Growth Rate (YoY) | 18.3% |
| Total Assets | $533.43 Million |
| Market Capitalization | $1.18 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Olema Pharmaceuticals Inc's assets at a significant premium (2.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Olema Pharmaceuticals Inc's assets grew by 18.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Olema Pharmaceuticals Inc (2018–2025)
The table below shows the annual total assets of Olema Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $533.43 Million | +18.28% |
| 2024-12-31 | $450.98 Million | +62.84% |
| 2023-12-31 | $276.94 Million | +28.43% |
| 2022-12-31 | $215.65 Million | -27.13% |
| 2021-12-31 | $295.94 Million | -13.65% |
| 2020-12-31 | $342.72 Million | +259537.88% |
| 2019-12-31 | $132.00K | -95.96% |
| 2018-12-31 | $3.27 Million | -- |
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive,… Read more